Tue 04/25/2023 09:55 AM
Relevant Documents:Preliminary OM
Covenant Analysis
German drugmaker Cheplapharm is offering €750 million senior secured fixed and floating rate notes due 2030 (“2030s”) to finance the
acquisition of worldwide rights (except in South Korea) to schizophrenia and bipolar disorder drug Zyprexa from Eli Lilly.
The covenant package for the 2030s is mostly similar to the covenant package of its existing senior secured notes due 2027 (“2027s”) and 2028 (“2028s”). Some basket capacities have...
This article is an example of the content you may receive if you subscribe to a product of Reorg Research, Inc. or one of its affiliates (collectively, “Reorg”). The information contained herein should not be construed as legal, investment, accounting or other professional services advice on any subject. Reorg, its affiliates, officers, directors, partners and employees expressly disclaim all liability in respect to actions taken or not taken based on any or all the contents of this publication. Copyright © 2024 Reorg Research, Inc. All rights reserved.